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The key role of T cells in the pathogenesis of cutaneous psoriasis has been well described 
in the last decade and the knowledge of the relative role of the different subsets of T cells 
in psoriasis pathogenesis has considerably evolved. Now, it is clear that IL-17A-producing 
T cells, including Th17/Tc17, have a central role in the pathogenesis of cutaneous psoria-
sis and therapies blocking the IL-17A pathway show high clinical efficacy. By contrast, the 
contribution of IFNγ-producing T cells has progressively become less clear because of the 
lack of efficacy of anti-IFNγ antibodies in clinical studies. In parallel, the role of CD8+ T cells 
specific for self-antigens has been revived and increasing evidence now indicates that in 
psoriatic skin the majority CD8+ T cells are present in the form of epidermal tissue-resident 
memory T cells. In the last years it also emerged the possibility of a contribution of T cell 
recirculation in the pathogenesis of psoriasis and its systemic manifestations. The aim of 
this review is to define a hierarchy for the different subsets of T cells in the T cell-mediated 
inflammatory cascade in psoriatic skin. This analysis will possibly help to distinguish the 
subsets that initiate the disease, those involved in the establishment of the self-sustaining 
amplification loop that leads to the cutaneous clinical manifestations and finally the sub-
sets that act as downstream players in established lesions. Specific T cell subpopulations 
finally will be considered for their possible role in propagating inflammation at distant sites 
and for representing a link with systemic inflammation and cardiovascular comorbidities.
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inTRODUCTiOn
Psoriasis is a chronically relapsing inflammatory disease of the skin affecting about 2% of the popula-
tion worldwide.
Histologically, psoriasis is characterized by three principal features: epidermal hyperplasia, 
leukocyte infiltrate, and an increased number of tortuous and leaky vessels in the dermis (1–3). In 
recent studies, the presence of lymphoid aggregates/memory T cell clusters in the dermis of psoriatic 
plaques has been reported (4, 5).
20–30% of patients with psoriasis also develops psoriatic arthritis (PsA) and there is evidence that 
psoriasis is associated with systemic inflammation and with comorbidities, such as cardiovascular 
disease (6–12).
With regards to the pathogenesis, it is now emerging that psoriasis is an immune-mediated disease 
with a central autoimmune component mediated by T  cells. Specifically, the disease pathogenesis 
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involves a dynamic interplay between dermal den dritic cells, T cells 
(CD8+ autoreactive T  cells, Th1, and Th17) and keratinocytes 
giving rise to a self-sustaining inflammatory cycle that develops 
around the TNF/IL-23/IL-17A axis (13–17). Despite this evidence, 
the hierarchical sequence of T cell-mediated events in the psoriatic 
inflammatory cascade is not completely defined. On the basis of 
the current literature and results of cytokine-blocking therapies it 
is possible to distinguish, in the T cell-mediated psoriatic inflam-
matory cascade, (i) an initial skin T cell activation phase, (ii) the 
establishment of chronic inflammation, (iii) the maintenance of 
clinically established lesions, and (iv) the egress from the skin of 
specific subsets of T cells that could possibly take part in the devel-
opment of extra-cutaneous manifestations of psoriasis, including 
joint inflammation and cardiovascular comorbidities (18, 19).
T CeLL HieRARCHY in THe FORMATiOn 
OF PSORiATiC PLAQUeS
T cell responses against self-antigens in psoriasis are initiated by 
dendritic cells in the dermis of pre-psoriatic skin (20). Mature 
dermal dendritic cells can produce TNFα and IL-23, present 
self-antigens, and stimulate the activation of autoreactive CD8+ 
T cells together with a fraction of CD4+ T cells polarized toward 
Th17 phenotype or the IL-17+IFNγ+ pathogenic Th1/Th17 as 
described by Annunziato and co-workers and Eisdmo and co-
workers (20–23).
Activated T cells can migrate to the epidermis and recognize 
epidermal autoantigens and possibly progress toward differen-
tiation to tissue-resident memory T  cells (TRM) characterized 
by CD69+CD103+CCR7−CD45RA−CD62L− phenotype (24, 25). 
Recognition of epidermal autoantigens by Tc1/Tc17 induces 
the secretion of cytokines, including IL-22, that mediate the 
initial phase of epidermal hyperproliferation and activation of 
keratinocytes (Figure 1A). These will produce chemokines and 
antimicrobial peptides, which lead to the progression of the 
inflammatory process (26–29).
Epidermal autoantigens include LL-37 antimicrobial peptide 
expressed by keratinocytes, keratin 17, and melanocyte-derived 
antigen ADAMTS-like protein 5 (ADAMTSL5) recognized by 
IL-17A-producing CD8+ T  cells, restricted by HLA-C*06:02 
(26, 30–35).
This evidence together with early studies strongly supports 
that CD8+ T cells represent the autoimmune core of the disease. 
In psoriatic skin lesions, CD8+ T cells accumulate in the form of 
TRM with a pathogenic IFNγ–IL-17A cytokine profile that were 
detected also in resolved psoriatic lesions and identified as poten-
tial mechanisms of site-specific disease memory (20, 25, 36–42).
The major role of CD8+ T cells is also strongly supported by 
the fact that the main psoriasis risk gene is the HLA-class I allele 
HLA-C*06:02 on psoriasis susceptibility locus 1 on chomo-
some 6 and additional HLA-class I alleles are associated with 
psoriasis (43, 44).
Among tissue-resident T cells in human psoriatic skin, Clark and 
co-workers have recently shown that the vast majority has an αβ 
TCR (42), despite γδ T cells have been reported to play a role in the 
production of IL-17A and maintenance of inflamma tion (45, 46).
As regards to the TCR repertoire, studies of TCRBV chain 
sequencing showed mono or oligoclonal expansions of T  cells 
mainly of CD8+ lineage in psoriatic skin (47–49). TCRBV expan-
sion indicates antigen-driven CD8+ T cell responses, whereas the 
CD4+ T cell fraction was reported to be polyclonal (50). In patients 
with cutaneous psoriasis, however, the presence of oligoclonal 
TCRBV expansion in peripheral blood is debated (51, 52). Two 
different studies of high-throughput sequencing of the entire TCR 
repertoire have shown that alongside with a limited oligoclonally 
expanded T cell subpopulation in psoriatic skin that was in part 
retained in resolved lesions, there was a vast majority of polyclonal 
T cells (42, 53). This data suggests that similarly to what has been 
described in PsA by Winchester and co-workers, antigen-driven 
mono and oligoclonally expanded T cell populations represent a 
limited component of the T cell reactions in psoriatic skin, whereas 
the vast majority is represented by polyclonal CD4+ T cells that are 
not present in resolved lesions (54).
This evidence together confers to autoreactive CD8+ T  cells 
a dominant role in the plaque formation and in psoriasis recur-
rence and possibly a common role in psoriasis and PsA. It also 
underlines the importance of mechanisms of T cell plasticity and 
polarization toward pathogenic phenotypes.
With respect to CD8 T cell targetability, a recent study on a 
AGR mouse model of psoriasis has reported the accumulation of 
epidermal CD8+ T cells during psoriasis development which was 
associated with IL-17A production and increased keratinocyte 
proliferation. Importantly, in this study injection of anti-CD8 
antibody completely prevented psoriasis development (29).
Nevertheless, it is likely that Tc1/Tc17 autoreactive CD8+ TRM 
cells overlap their features and functions with the cells that under 
physiological conditions work as immune sentinels at barrier tis-
sue. For this reason in a clinical setting, it could be difficult to tar-
get epidermal CD8+ TRM cells by the available immunotherapeutic 
tools without incurring in major adverse effects (20, 28, 29, 37).
As regards T helper cells, they have been reported to be more 
abundant in psoriatic skin lesions. While initially they were 
described mainly as Th1  cells, more recently the attention has 
been focused on IL-17-producing cells and the IL-23/Th17 axis 
clearly emerged as central in the control of the pro-inflammatory 
cycle in psoriatic plaques (14, 15). The high efficacy and fast out-
come of IL-17A blocking therapies in resolving cutaneous clinical 
symptoms has strongly supported this concept (28, 55, 56). In 
addition, at skin level an expanded subset of T cells that produces 
IL-22 but not IL-17A (Th22) with a main role in the induction of 
acanthosis was identified. Importantly, these cells were found to 
be present also in resolved psoriatic lesions (57, 58).
In line with the key role of IL-17A, the main gene variants 
associated with psoriasis outside the MHC locus are single 
nucleotide polymorphisms, belonging to the IL-23/IL-17A axis 
(IL23R, IL12B, and IL23A) and the NF-κB pathway (TNFAIP3) 
(44, 59). It is, however, possible to hypothesize that Th17 or 
pathogenic Th1/Th17 cells could be expanded in the dermis as an 
event downstream of the epidermal autoimmune TRM and occurs 
through bystander activation mechanisms like the one described 
by Winchester and co-workers in psoriatic synovial tissues (54).
In this view, the cycle that develops around the IL-23/IL-17A 
axis could involve some antigen-driven populations and a 
FigURe 1 | T cell-mediated events in the psoriatic inflammatory cascade. (A) Activation of autoreactive T cells by self-antigens presented in the dermal lymphoid 
aggregates. Establishment of CD8+ TRM cells as central autoimmune component of disease pathogenesis and potential mechanisms of site-specific disease 
memory. (B) Polyclonal T cells proliferation and Th17/Tc17-mediated inflammation around the IL-23/IL-17A axis. (C) Recruitment of Th1/Tc1 cells, with multiple 
specificities, from the blood stream, induced by CXCL10 chemokines. Recirculation of T cells from the skin to the blood can spread inflammation at systemic level 
and at distant sites.
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considerable fraction of polyclonally expanded T cells that can 
represent the second step of the pro-inflammatory cascade, 
responsible for the amplification of inflammation and for the 
exacerbation of clinical symptoms (Figure 1B).
As a consequence of the strong evidence of the central role of 
IL-17A-producing cells, the relevance of Th1 cells and IFNγ has 
become less clear. In lesional skin of psoriasis patients, Th1 cells 
and IFNγ levels are clearly increased (60, 61). However, in a small 
pilot study in patients with psoriasis, treatment with a humanized 
anti-IFNγ antibody induced improvement of histological and 
some clinical parameters but only minor therapeutic effects (62).
These controversial findings focus on the complexity of the 
interplay between the Th1/Tc1 and Th17/Tc17 cells in the patho-
genesis of psoriasis and it is not clear how the marked increase of 
IFNγ and IFNγ-producing cells in psoriatic skin can actually link 
with the failure of IFNγ-blockade to show therapeutic efficacy.
Results from a study by Kryczek et al. have suggested that IFNγ 
exerts one of its effects by programming myeloid dendritic cells 
to produce CCL20, ligand of CCR6, and to secrete IL-23. This 
in turn would favor the recruitment and expansion of IL-17A-
producing cells (63, 64). On the other hand, IFNγ mRNA is 
markedly upregulated in psoriatic plaques and noticeably IFNγ- 
induced genes, such as CXCL9, CXCL10, and CXCL11 are strongly 
increased in psoriatic lesions (65).
In line with this evidence, we have previously reported gene 
expression data in psoriatic skin showing significant enhancement 
of CXCR3 and CXCL10 expression with an inverse correlation 
between the circulating fraction of CXCR3+ CD4+ effector memory 
T cells and the severity of cutaneous psoriasis (66, 67). Therefore, 
we can postulate an ultimate downstream phase in the psoriatic 
cascade, driven by the CXCL10/CXCR3 axis which induces the 
recruitment of Th1/Tc1 from the blood stream (Figure 1C).
T CeLLS in THe PATHOgeneSiS OF PsA
Psoriatic arthritis develops in a fraction of patients with psoriasis 
and in the majority of cases it follows the development of the 
cutaneous disease by a mean of 10 years (68).
In addition to the skin, PsA targets the attachment sites of liga-
ment to bone (entheses), the peripheral joints, and the spine (12, 69).
Enthesitis is indeed a distinctive feature of PsA and it has been 
hypothesized that, in PsA joints, inflammation can start from 
the entheses. The disease progression, in patients with PsA, can 
finally lead to destructive bone loss and 67% of patients exhibit 
signs of erosive bone disease (70).
Similarly to psoriasis, T cells are involved in the pathogenesis 
of PsA and reduction of CD3+ cells in PsA synovium correlated 
with the clinical response to biological therapies (71).
In PsA patients, Canete and co-workers have evidenced the 
presence of lymphoid aggregates in synovial tissues that was signi-
ficantly reduced by TNF-blocking agents. This result could be paral-
leled by the observation of lymphoid aggregates in psoriatic skin 
and the role of CCR7/CCL19 axis, modulated by TNF in the initial 
clustering of dendritic cells and T cells in the dermis (4, 5, 72–75).
In line with the concept of shared pathogenic mechanisms 
between psoriasis and PsA, Belasco and colleagues provided the 
evidence that gene expression in PsA synovium was more closely 
related to gene expression in the PsA patient skin than to gene 
expression in the synovium of patients with other forms of arthri-
tis. IL17 gene, however, was upregulated more in skin than in the 
synovium, whereas TNF and IFNγ were similarly upregulated in 
both tissues (76).
As regards the TCR repertoire analysis in PsA joints, Tassiulas 
et al. (47) showed oligoclonal and monoclonal T cell expansions in 
the synovial tissue, some of which were shared with the skin. In a 
subsequent study, Curran et al. performed TCR β-chain nucleotide 
sequencing in peripheral blood and synovial tissues/fluid showing 
that 76% of the clones in inflamed tissues were polyclonal, whereas 
12% of the expanded clones had structurally homologous CDR3 
β-chain sequence and were only CD8+ in lineage (54). Interestingly, 
some of the expanded CD8+ clones identified in the synovial 
tissue were present also in peripheral blood and joint fluid.
A second population of moderately expanded inflammation-
related clones, that were either of CD4+ or CD8+ lineage, was 
identified only in inflamed synovial tissue and joint fluid. These 
cells could represent a secondary consequence of the inflamma-
tion induced by other proliferating clones.
Finally, one major population consisted of unexpanded 
polyclonal CD4+ T cells that did not persist in the tissue during 
methotrexate treatment, were most likely effector memory CD4+ 
T cells recruited by inflammatory chemokines released by other 
cell populations. The lack of clonal expansion in CD4+ T  cells 
suggests a lower hierarchical role in driving inflammation.
These findings together suggest a role for cognate T  cell 
responses in the pathogenesis of PsA and further suggest that 
T  cell clones specific for identical or homologous antigens in 
skin and synovium may represent central elements in promoting 
inflammation in both tissues (47).
It remains to be established how self-reactive T cell responses in 
the skin, can be mechanistically linked to the one found in the syno-
vial fluid and how these events can occur with years of time-lapse.
To this end, genetic association studies can provide some 
interpretation keys. In addition to the HLA-C*06:02 which is 
common with psoriatic plaque, additional HLA-alleles are associ-
ated with PsA. These HLA-alleles include B*08:01:01, B*27:05:02, 
B*38:01:01, and B*39:01:01 (77).
This underlines the importance of CD8+ T  cells recognizing 
HLA-class I associated self-antigens in the pathogenesis of PsA and 
suggests that the autoimmune basis of PsA may be even broader 
than the one of cutaneous psoriasis. In this view, enthesis that 
anatomically links mechanical stress to immunologically active 
tissue (synovium), could be central for the pathogenesis (78).
Entheses are commonly subject to microdamage associated 
with local cytokine release, which may evolve into subsequent 
inflammation (79, 80). Inflammation in turn can favor cross-
presentation of self-antigens.
It is, therefore, possible that recirculation of pathogenic skin T cells 
recognizing common self-antigens can start subclinical inflamma-
tion by localizing to the synovioenthesial complex (Figure 1C).
Patients with psoriatic disease have shown an increased level 
of circulating CCR6+ CD4+ TEM and TEFF cells that correlated posi-
tively with systemic inflammation (66). Therefore, it is possible to 
hypothesize that a fraction of IL-17-producing T cells recirculates 
from the skin and relocalize to the entheses.
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This is reinforced by the findings of Sherlock et al. reporting 
that IL-17A+ cells locate mainly at the entheses and synovial tissues 
and by the evidence that among the genetic risk factors outside the 
MHC locus there are gene variants falling into the IL-23/IL-17A 
axis (77, 80–85). Importantly, it has been reported that IL-23 is 
expressed in synovial membrane with ectopic lymphoid tissue (78).
The fraction of IL-17A-producing cells recirculating from the 
skin could, therefore, determines subclinical inflammation and 
favor, in the long-term, cross-presentation of self-antigens and 
epitope spreading phenomena (73, 78).
In established PsA, it has also been reported an increased 
percentage of IL-17A-producing CD8+ T cells in synovial fluid 
which correlate with bone erosion and disease severity (86–88).
In the light of a hierarchical T cell clonality in psoriatic tis-
sue and the evidence of the multiple-specific clones, including 
EBV-specific clones, observed in synovial fluid, we can postulate 
that massive recruitment of T cells with Th1/Tc1 phenotype from 
peripheral blood occurs as a consequences of inflammatory 
chemokine release (54). By analogy with the observation in psori-
atic skin and by evidence from the data provided by Gladman and 
co-workers it is possible that CXCL10/CXCR3 axis can act as a 
downstream cell recruitment mechanism of tissue inflammation 
common to cutaneous psoriasis and PsA (89–91).
T CeLLS in PSORiASiS-ASSOCiATeD 
CARDiOvASCULAR COMORBiDiTieS
Increasing epidemiological and clinical evidence indicates that 
psoriasis is an independent risk factor for cardiovascular disease 
(92, 93).
As a consequence of poorly controlled tissue inflammation, 
psoriasis patients can develop systemic inflammation and ath-
erosclerosis. In this process, it has been postulated that inflamed 
tissue-derived factors or cells may directly affect distant vessels for 
the development of athero-thrombosis (7, 94, 95). Nevertheless, 
the cellular mechanisms that link the cutaneous manifestations of 
plaque psoriasis with the initiation and progression of atheroscle-
rosis in psoriasis patients are largely unknown.
A recent study on human tissues showed that psoriasis and 
atherosclerosis exhibit significant overlap of their transcriptomes 
and in particular that TNF, IFNg, and IFNγ-induced genes, which 
are common between psoriasis and atherosclerosis may provide 
the link between the two diseases (96). By contrast, IL-17A and 
CCL20 were higher in psoriasis than in atherosclerotic tissue, 
whereas IL17R gene was expressed at similar levels.
Because of the link between IL-17A and neutrophil infiltration 
in atherosclerotic plaques and its key role in the pathogenesis of 
psoriasis it has been suggested that the IL-17A/neutrophil axis 
could take part to atherogenesis associated with psoriatic disease 
(97). Nevertheless, the role of IL-17A in psoriasis-associated 
athero sclerosis is still controversial. Indeed, Usui et al. reported 
that IL-17A deficiency protected against atherosclerosis in 
apoE−/− mice due to reduced macrophage infiltration and inflam-
matory cytokine secretion in the lesions (98).
Other mouse studies have indicated that IL-17A may promote 
plaque stability by contributing to fibrous cap formation (99). 
Collectively, the results indicate that IL-17A may exert both 
anti- and pro-atherogenic effects, depending on the inflamma-
tory context. However, further studies will be necessary to clarify 
the contribution of T cells recirculating from the psoriatic plaque 
in the development of atherosclerosis.
iMPLiCATiOnS FOR THe DeveLOPMenT 
OF THeRAPeUTiC PROTOCOLS
From this analysis it emerges a differential contribution of the 
individual subsets of T cells in the pathogenesis of psoriasis, PsA, 
and associated cardiovascular comorbidities namely, athero-
sclerosis. In particular, TNFα has a relevant role in inducing the 
CCL19/CCR7-mediated formation of clusters of dendritic cells 
and T cells in both psoriasis and PsA. It also emphasizes the role of 
IL-23/IL-17 axis in the amplification loop critical for the clinical 
manifestations of cutaneous psoriasis and possibly in the initial 
phase of join inflammation.
On the other hand, the possibility of a third step of CXCL10/
CXCR3-mediated recruitment of Th1/Tc1 cells from the blood 
stream may explain the apparent controversy between the high 
amount of IFNγ-producing cells and the low therapeutic efficacy 
of anti-IFNγ antibody treatment.
COnCLUSiOn
By defining the hierarchy of the T  cell-mediated events of the 
psoriatic cascade in psoriatic plaques it is possible to distinguish a 
core antigen-driven oligo or monoclonally expanded autoreactive 
CD8+ T cell component, a secondary self-reactive CD4+ T cell 
component, a polyclonal CD4+ Th17 and pathogenic Th1/Th17 
population amplified by the IL-23/IL-17A axis, and a downstream 
recruitment of CXCR3+ T cells with different specificities induced 
by the upregulation of CXCL10 chemokine. Similarly in PsA the 
analysis of the TCR repertoire has evidenced central antigen-
driven expansion of mainly CD8+ T cells and broad polyclonal 
CD4+ T cells expansion. In addition, a group of common clones 
were also expanded in peripheral blood of patients with PsA 
and T cell clones specific for identical or homologous antigens 
were present in both skin and in synovial tissues. These may 
represent central elements in promoting inflammation in both 
tissues. In addition, oligoclonally expanded clones in peripheral 
blood of patients with PsA may also suggest that T cell recircula-
tion can represent a mechanistic link between skin and joints 
inflammation.
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